Brokerages continue to remain constructive on select stocks across the healthcare, banking, defence, pharmaceuticals and specialty chemicals sectors, backed by improving earnings prospects and strong business fundamentals.We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Nuvama on Dr Lal PathLabs
Nuvama on Dr Lal PathLabs: Buy| Target Rs 2140 (vs Rs 1900)| LTP Rs 1756| Potential Upside 21%Nuvama has reiterated its 'Buy' rating on Dr Lal PathLabs and raised the target price to Rs 2,140 from Rs 1,900, implying a potential upside of 21% from the current market price of Rs 1,756.
Nuvama on IDFC First Bank
Nuvama on IDFC First Bank: Upgrade to buy from hold| Target Rs 95| LTP Rs 80| Potential Upside 18%Nuvama has upgraded IDFC First Bank to 'Buy' from 'Hold' and assigned a target price of Rs 95, indicating a potential upside of 18% from the current market price of Rs 80.
AnandRathi on Jubilant Ingrevia
AnandRathi on Jubilant Ingrevia: Buy| Target Rs 980| LTP Rs 725| Potential Upside 35%Anand Rathi has maintained a 'Buy' rating on Jubilant Ingrevia with a target price of Rs 980, suggesting a potential upside of 35% from the current market price of Rs 725.
AnandRathi on Hindustan Aeronautics
AnandRathi on Hindustan Aeronautics: Buy| Target Rs 5431| LTP Rs 4569| Potential Upside 18%Anand Rathi has reiterated its 'Buy' recommendation on Hindustan Aeronautics with a target price of Rs 5,431, implying a potential upside of 18% from the current market price of Rs 4,569.
Emkay Global on Granules India
Emkay Global on Granules India: Buy| Target Rs 950| LTP Rs 833| Potential Upside 14%Emkay Global has maintained its 'Buy' rating on Granules India and set a target price of Rs 950, indicating a potential upside of 14% from the current market price of Rs 833.(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
